article · Clinical Infectious Diseases

The Frequency and Incidence of QT Prolongation With Extended Use of Bedaquiline or Delamanid in a Large, Multi-Country Multidrug-Resistant/Rifampicin-Resistant Tuberculosis Cohort

Uzma Khan
Patrick Nkunkanyirazo
Nana Kiria
Cecilio L Tan
Edwin H. Herrera-Flores
Shahid Mamsa
Helena Huerga
Nathalie Lachenal
Jamil Faqirzai
Mathieu Bastard
Razia Fatima
Fauziah Asnely Putri
Jude Beauchamp
Nara Melikyan
Carole D. Mitnick
Catherine Hewison
Michael Rich
Muhammad Rafi Siddiqui
Munira Khan
Afshan K. Isani
Cut Yulia Indah Sari
Ye Yint Naing
Molly F. Franke
Yerkebulan Algozhin
Stalz Charles Vilbrun
Francis Varaine
Luan Nguyen Quang Vo
Saki Nagashima
Shirajul Islam
Saman Ahmed
Amsalu Bekele
Kwonjune J. Seung
Palwasha Khan

20245 citationsOpen accessAddis Ababa University

Abstract

We demonstrate that Bdq and/or Dlm use beyond 6 months is safe in longer MDR/RR-TB regimens with most clinically relevant QT prolongation events occurring in the first 6 months. Electrocardiogram (ECG) monitoring for early identification of QT prolongating events is possible in programmatic conditions.

Research topics

Tuberculosis Research and Epidemiology
Pneumonia and Respiratory Infections
Cancer therapeutics and mechanisms

Sustainable Development Goals

Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1093/cid/ciae601

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.